Alembic Pharmaceuticals Gestione
Gestione criteri di controllo 1/4
Alembic Pharmaceuticals Il CEO è Chirayu Amin, nominato in Apr2016, e ha un mandato di 8.58 anni. la retribuzione annua totale è ₹ 193.80M, composta da 48.4% di stipendio e 51.6% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 2.13% delle azioni della società, per un valore di ₹ 4.73B. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 1.4 anni e 9.8 anni.
Informazioni chiave
Chirayu Amin
Amministratore delegato
₹193.8m
Compenso totale
| Percentuale dello stipendio del CEO | 48.4% |
| Mandato del CEO | 8.6yrs |
| Proprietà del CEO | 2.1% |
| Durata media del management | 1.4yrs |
| Durata media del Consiglio di amministrazione | 9.8yrs |
Aggiornamenti recenti sulla gestione
Recent updates
Alembic Pharmaceuticals Limited's (NSE:APLLTD) Intrinsic Value Is Potentially 17% Below Its Share Price
Sep 25
Is Alembic Pharmaceuticals (NSE:APLLTD) Using Too Much Debt?
Sep 03Alembic Pharmaceuticals Limited Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
Aug 13Market Participants Recognise Alembic Pharmaceuticals Limited's (NSE:APLLTD) Earnings Pushing Shares 25% Higher
Jul 20Alembic Pharmaceuticals (NSE:APLLTD) Seems To Use Debt Rather Sparingly
Jun 03Does This Valuation Of Alembic Pharmaceuticals Limited (NSE:APLLTD) Imply Investors Are Overpaying?
May 11Results: Alembic Pharmaceuticals Limited Exceeded Expectations And The Consensus Has Updated Its Estimates
Feb 08Subdued Growth No Barrier To Alembic Pharmaceuticals Limited (NSE:APLLTD) With Shares Advancing 25%
Jan 21Is Alembic Pharmaceuticals (NSE:APLLTD) A Risky Investment?
Jan 05Here's Why Alembic Pharmaceuticals (NSE:APLLTD) Can Manage Its Debt Responsibly
Sep 27Alembic Pharmaceuticals (NSE:APLLTD) Seems To Use Debt Quite Sensibly
Jun 09A Look At The Fair Value Of Alembic Pharmaceuticals Limited (NSE:APLLTD)
Apr 13Is Alembic Pharmaceuticals (NSE:APLLTD) A Risky Investment?
Feb 22Alembic Pharmaceuticals Limited (NSE:APLLTD) Shares Could Be 21% Below Their Intrinsic Value Estimate
Jan 04We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Alembic Pharmaceuticals Limited's (NSE:APLLTD) CEO For Now
Nov 05Here's Why Alembic Pharmaceuticals (NSE:APLLTD) Has A Meaningful Debt Burden
Aug 10Estimating The Intrinsic Value Of Alembic Pharmaceuticals Limited (NSE:APLLTD)
Jul 20We Think Alembic Pharmaceuticals (NSE:APLLTD) Is Taking Some Risk With Its Debt
May 05Analisi delle retribuzioni degli amministratori delegati
| Data | Compenso totale | Stipendio | Guadagni aziendali |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | ₹6b |
| Mar 31 2024 | ₹194m | ₹94m | ₹6b |
| Dec 31 2023 | n/a | n/a | ₹6b |
| Sep 30 2023 | n/a | n/a | ₹5b |
| Jun 30 2023 | n/a | n/a | ₹5b |
| Mar 31 2023 | ₹88m | ₹88m | ₹3b |
| Dec 31 2022 | n/a | n/a | ₹2b |
| Sep 30 2022 | n/a | n/a | ₹3b |
| Jun 30 2022 | n/a | n/a | ₹3b |
| Mar 31 2022 | ₹280m | ₹80m | ₹5b |
| Dec 31 2021 | n/a | n/a | ₹8b |
| Sep 30 2021 | n/a | n/a | ₹9b |
| Jun 30 2021 | n/a | n/a | ₹10b |
| Mar 31 2021 | ₹315m | ₹65m | ₹11b |
| Dec 31 2020 | n/a | n/a | ₹12b |
| Sep 30 2020 | n/a | n/a | ₹11b |
| Jun 30 2020 | n/a | n/a | ₹10b |
| Mar 31 2020 | ₹265m | ₹65m | ₹8b |
| Dec 31 2019 | n/a | n/a | ₹7b |
| Sep 30 2019 | n/a | n/a | ₹7b |
| Jun 30 2019 | n/a | n/a | ₹6b |
| Mar 31 2019 | ₹255m | ₹55m | ₹6b |
| Dec 31 2018 | n/a | n/a | ₹6b |
| Sep 30 2018 | n/a | n/a | ₹5b |
| Jun 30 2018 | n/a | n/a | ₹4b |
| Mar 31 2018 | ₹220m | ₹55m | ₹4b |
Compensazione vs Mercato: La retribuzione totale di Chirayu ($USD 2.30M ) è superiore alla media delle aziende di dimensioni simili nel mercato Indian ($USD 575.20K ).
Compensazione vs guadagni: La retribuzione di Chirayu è aumentata di oltre il 20% nell'ultimo anno.
AMMINISTRATORE DELEGATO
Chirayu Amin (78 yo)
8.6yrs
Mandato
₹193,800,000
Compensazione
Mr. Chirayu Ramanbhai Amin, M.B.A. (U.S.A.), has been Chief Executive Officer of Alembic Pharmaceuticals Limited since April 27, 2016. Mr. Amin served as Managing Director of Alembic Pharmaceuticals Limite...
Gruppo dirigente
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| Executive Chairman & CEO | 8.6yrs | ₹193.80m | 2.13% ₹ 4.7b | |
| Managing Director | less than a year | ₹190.90m | 0.59% ₹ 1.3b | |
| MD & Executive Director | 9.6yrs | ₹122.20m | 0.51% ₹ 1.1b | |
| Director of Finance | no data | ₹56.90m | Nessun dato | |
| Head of Technical Operations | less than a year | Nessun dato | Nessun dato | |
| Chief Scientific Officer | no data | ₹8.41m | Nessun dato | |
| Company Secretary & Compliance Officer | 1.6yrs | Nessun dato | Nessun dato | |
| Chief Business Development Officer | no data | ₹8.30m | 0.51% ₹ 1.1b | |
| Senior Vice President | no data | ₹8.12m | Nessun dato | |
| Senior Vice President of Finance | no data | ₹9.20m | Nessun dato | |
| Senior Vice President of Supply Chain | no data | Nessun dato | Nessun dato | |
| Head of International Business & Strategy | 1.3yrs | Nessun dato | Nessun dato |
1.4yrs
Durata media
63yo
Età media
Gestione esperta: Il team dirigenziale di APLLTD non è considerato esperto (durata media 1.4 anni), il che suggerisce un nuovo team.
Membri del Consiglio di amministrazione
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| Executive Chairman & CEO | 14.4yrs | ₹193.80m | 2.13% ₹ 4.7b | |
| MD & Executive Director | 11.5yrs | ₹122.20m | 0.51% ₹ 1.1b | |
| Director of Finance | 14.4yrs | ₹56.90m | Nessun dato | |
| Independent Non-Executive Director | 9.8yrs | ₹2.28m | Nessun dato | |
| Independent Director | less than a year | Nessun dato | Nessun dato | |
| Independent Director | 2.8yrs | ₹1.82m | Nessun dato | |
| Independent Director | 1.5yrs | ₹2.10m | Nessun dato |
9.8yrs
Durata media
59yo
Età media
Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di APLLTD sono considerati esperti (durata media dell'incarico 9.8 anni).